NCT02535312 - Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

October 17, 2025

Conditions

Advanced Malignant Solid NeoplasmAdvanced Peritoneal Malignant MesotheliomaAdvanced Pleural Malignant MesotheliomaRecurrent Peritoneal Malignant MesotheliomaRecurrent Pleural Malignant MesotheliomaRefractory Malignant Solid NeoplasmUnresectable Solid Neoplasm

Interventions

DRUG

Cisplatin

Given IV

DRUG

Methoxyamine

Given PO

DRUG

Pemetrexed Disodium

Given IV

Trial Locations (14)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

37204

Vanderbilt Breast Center at One Hundred Oaks, Nashville

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

55905

Mayo Clinic in Rochester, Rochester

80045

UCHealth University of Colorado Hospital, Aurora

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91105

Keck Medical Center of USC Pasadena, Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH